Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling

PURPOSE: Currently, the exact role of estrogen receptor (ER) signaling in pancreatic cancer is unknown. Recently, we showed that expression of phosphorylated ERβ correlates with a poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). Here, we hypothesized that raloxifene, a FDA-ap...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Oncol (Dordr)
Main Authors: Pozios, Ioannis, Seel, Nina N., Hering, Nina A., Hartmann, Lisa, Liu, Verena, Camaj, Peter, Müller, Mario H., Lee, Lucas D., Bruns, Christiane J., Kreis, Martin E., Seeliger, Hendrik
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Netherlands 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7906944/
https://ncbi.nlm.nih.gov/pubmed/32940862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13402-020-00559-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados